Simplified treatment for a cause of sight loss offers eye-opening savings for hospitals

  • New study shows that simplifying a surgical technique to treat an important cause of sight loss around the world could be 10 per cent the cost for hospitals, but just as effective, and help to make the procedure more accessible for patients
  • The simplified procedure was first developed in 2012 to treat patients in India and despite having a profound impact on eye surgery in this country, it has yet to be adopted by surgeons elsewhere, including in the UK
  • The technique is a different way of using stem cell therapy to replace damaged or lost epithelial cells which protect the cornea
  • The study reveals the simplified procedure is safer and even more effective at treating damaged corneas in children

Simplifying a surgical technique to treat one of the important causes of sight loss around the world could deliver major savings for eye hospitals and help bring the treatment to more patients, according to new research.

The method, developed by Professor Sheila MacNeil, a tissue engineer at the University of Sheffield, and Dr Virender Sangwan, an ophthalmic surgeon at L V Prasad Eye Institute in Hyderabad, India, offers a different way of using stem cell therapy to treat damaged epithelial cells which protect the cornea.

First developed in 2012 for patients in India, the method has now become routine practice in this country and has had a profound impact on the treatment of eyes damaged by accident or disease. However, despite its success, the procedure is yet to be adopted more widely by surgeons in other countries.

Now, a new paper in the British Journal of Ophthalmology has revealed that as well as being as effective as the technique currently used by eye surgeons in other countries, the procedure is also only 10 per cent the cost.

Currently patients outside of India with damaged epithelial cells can only be treated in specialist centres. Here, cells from the unaffected eye are cultured over several weeks in specialist laboratories and grafted back to the scarred eye using a human amniotic membrane – derived from donated placenta – to deliver them.

While the success with this technique is good, there are thought to be approximately 12 centres in the world offering this technology to patients. In terms of accessibility, there is only one company in Europe able to offer this procedure on a commercial basis.

The procedure developed by researchers in Sheffield and India is much simpler with one modification to the existing technique. It uses tiny pieces of tissue taken from the unaffected eye to regrow a new cornea epithelium on the damaged eye – rather than culturing the patient’s corneal cells in a specialist laboratory over several weeks.

Essentially the simplified technique uses the patient’s own body as the incubator for the expansion of stem cells found in small pieces of the limbus placed on amniotic membrane on the damaged eye. Cells migrate out of the limbal pieces and join up to form a new corneal epithelium over several weeks.

The effectiveness of the procedure has been well documented in over 30 peer-reviewed studies, as summarised in the British Journal of Ophthalmology, and for the first time the authors looked at the health economics of the simplified technique versus the original technique.

The technique has been found to be just as effective at treating patients with damaged epithelial cells as the current method used by eye surgeons over the last two decades and found to be even more effective when treating children.

Professor Sheila MacNeil, Professor of Tissue Engineering at the University of Sheffield, said: “The new technique we have developed has had a huge impact on the way patients with damaged corneas have been treated in India, and now this new research shows that as well as being an effective treatment it is also much cheaper to do than the traditional method that is still being used by surgeons throughout the rest of the world. While this was developed to reduce the costs and numbers of surgeries to make the technique more accessible for patients in India this simplification of the technique is very timely for all countries where hospitals are facing financial pressures and surgical resource issues in response to the Covid-19 pandemic.”

Dr Virender Sangwan, Ophthalmic Surgeon at the L V Prasad Eye Institute in Hyderabad, India, said: The SLET is a game changer for the limbal stem cell transplantation in treatment of damaged corneas with limbal stem cell deficiency. The technique has truly democratised the treatment and made it affordable and safer. We the surgeons are grateful to Professor MacNeil and the University of Sheffield for making it happen and for being part of the journey.”

/Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.